NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference

Rhea-AI Summary

NeuroBo Pharmaceuticals, Inc. (NRBO) announces participation in the BIO CEO & Investor Conference for one-on-one investor meetings and business development discussions.

CAMBRIDGE, Mass., Feb. 12, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Acting Chief Financial Officer, will participate in one-on-ones with investors and business development meetings with biopharmaceutical executives at the BIO CEO & Investor Conference, taking place February 26-27, 2024 in New York.

Interested parties can request a meeting through the BIO One-on-One Partnering System™: https://partnering.bio.org/ceo2024 

To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.

For more information, please visit www.neurobopharma.com.

Contact:

NeuroBo Pharmaceuticals
Marshall H. Woodworth
Interim Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com 

View original content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-to-participate-in-the-bio-ceo--investor-conference-302058649.html

SOURCE NeuroBo Pharmaceuticals, Inc.

FAQ

What event is NeuroBo Pharmaceuticals participating in?

NeuroBo Pharmaceuticals is participating in the BIO CEO & Investor Conference for one-on-one investor meetings and business development discussions.

When is the BIO CEO & Investor Conference taking place?

The BIO CEO & Investor Conference is scheduled for February 26-27, 2024, in New York.

Who will be representing NeuroBo Pharmaceuticals at the conference?

Hyung Heon Kim, President and CEO, and Marshall H. Woodworth, Acting CFO, will be representing NeuroBo Pharmaceuticals at the conference.

How can interested parties schedule a meeting with NeuroBo Pharmaceuticals?

Interested parties can request a meeting through the BIO One-on-One Partnering System™ at https://partnering.bio.org/ceo2024. For meetings outside the conference, contact Michael Miller at mmiller@rxir.com.